darunavir has been researched along with Hyperlipemia in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, HJ; Colletti, L; Degoey, DA; Dekhtyar, T; Flentge, CA; Flosi, WJ; Grampovnik, DJ; Kati, WM; Kempf, DJ; Klein, LL; Mamo, M; Marsh, KC; Mo, H; Molla, A; Morfitt, DC; Nguyen, B; Randolph, JT; Schmidt, JM; Stoll, V; Swanson, SJ; Yeung, CM | 1 |
Curran, A; Ribera Pascuet, E | 1 |
1 trial(s) available for darunavir and Hyperlipemia
Article | Year |
---|---|
[Darunavir as first-line therapy. The TITAN study].
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Darunavir; Diarrhea; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lopinavir; Male; Prognosis; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Sulfonamides | 2008 |
1 other study(ies) available for darunavir and Hyperlipemia
Article | Year |
---|---|
2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.
Topics: Animals; Binding Sites; Biological Availability; Caco-2 Cells; Carbamates; Cell Membrane Permeability; Crystallography, X-Ray; Dipeptides; Dogs; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Hyperlipidemias; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Mutation; Putrescine; Pyridines; Rats; Rats, Gunn; Stereoisomerism; Structure-Activity Relationship | 2009 |